论文信息 - PPAR&ggr; agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR‐TKI‐resistant lung adenocarcinoma cells via the PPAR&ggr;/PTEN/Akt pathway - 字舞流文

PPAR&ggr; agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR‐TKI‐resistant lung adenocarcinoma cells via the PPAR&ggr;/PTEN/Akt pathway

L. Ding | Jian-zhong Wu | Jifeng Feng | H. Cao | Xia Zhao | Rong Ma | J. Ni | Lei-lei Zhou | H. Li | Siwen Liu | Zhuo Wang | Shuchen Dong | Fan Fan | Yuanyuan Du | Rui Lou | Jianzhong Wu